Koru Lifescience Limited

Koru Lifescience Limited is a pharmaceutical research and development group that provides advanced technological platforms and contract development services for the pharmaceutical industry. Established in 2017, the company focuses on agile drug development, including drug repurposing, differentiated product development, and the creation of personalized or stratified medicine. Their technical capabilities span a wide range of pharmaceutical dosage forms—including solids, semi-solids, liquids, and specialized formats like injectables and inhalants—supported by platforms such as osmotic drug delivery systems, hot melt extrusion, and micro-nanosuspensions. The company emphasizes a patient-centric approach to research, utilizing complex analytical development, stability studies, and regulatory affairs to bring therapies to market more efficiently.

These services are designed to assist partners and clients in accelerating the development of therapies for serious human diseases while addressing challenges related to bioavailability, extended drug release, and production costs. By offering R&D collaborative solutions and high-barrier intellectual property development, Koru Lifescience aims to improve medical outcomes and reduce off-target toxicity. Their work is intended to optimize current products and create new, accessible treatment pathways, helping to navigate the complexities of modern biology and chemistry to address unmet medical needs. The company has maintained a focus on productive innovation to deliver greater benefits to patients and healthcare providers.